173 related articles for article (PubMed ID: 32726870)
1. Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [
Dahl K; Turner T; Vasdev N
J Labelled Comp Radiopharm; 2020 Sep; 63(11):482-487. PubMed ID: 32726870
[TBL] [Abstract][Full Text] [Related]
2. Preliminary PET imaging of [
Boyle AJ; Lindberg A; Tong J; Zhai D; Liu F; Vasdev N
J Labelled Comp Radiopharm; 2024 May; 67(6):235-244. PubMed ID: 37691152
[TBL] [Abstract][Full Text] [Related]
3. [
Skaddan MB; Wooten DW; Wilcox KC; Voorbach MJ; Reuter DR; Jia ZJ; Foster-Duke KD; Hickson JA; Vaidyanathan S; Reed AD; Tovcimak AE; Guo Q; Comley RA; Lee L; Finnema SJ; Mudd SR
Mol Imaging Biol; 2022 Oct; 24(5):830-841. PubMed ID: 35482146
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).
Owens TD; Smith PF; Redfern A; Xing Y; Shu J; Karr DE; Hartmann S; Francesco MR; Langrish CL; Nunn PA; Gourlay SG
Clin Transl Sci; 2022 Feb; 15(2):442-450. PubMed ID: 34724345
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
[TBL] [Abstract][Full Text] [Related]
6. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
7. Radiosynthesis of the diastereomerically pure (E)-[
Bdair H; Tsai IH; Smart K; Benkelfat C; Leyton M; Kostikov A
J Labelled Comp Radiopharm; 2019 Oct; 62(12):860-864. PubMed ID: 31418468
[TBL] [Abstract][Full Text] [Related]
8. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of ([(11)C]carbonyl)raclopride and a comparison with ([(11)C]methyl)raclopride in a monkey PET study.
Rahman O; Takano A; Amini N; Dahl K; Kanegawa N; Långström B; Farde L; Halldin C
Nucl Med Biol; 2015 Nov; 42(11):893-8. PubMed ID: 26272268
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
12. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
13. Absorption, Metabolism, and Excretion of [
Nicolas O; Moliner P; Soubayrol P; Vitse O; Roy S; Cabanis MJ; Turner T; Klieber S; Muccio S; Arabeyre C; Brun P
Clin Drug Investig; 2023 Aug; 43(8):653-665. PubMed ID: 37642857
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
15. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
[TBL] [Abstract][Full Text] [Related]
17. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
Kawahata W; Asami T; Kiyoi T; Irie T; Kashimoto S; Furuichi H; Sawa M
J Med Chem; 2021 Oct; 64(19):14129-14141. PubMed ID: 34529443
[TBL] [Abstract][Full Text] [Related]
18. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
Huang W; Wang S; Zhang Z; Zhang C; Zeng S; Liang M; Shen Z; Liu X
Bioorg Chem; 2020 Dec; 105():104377. PubMed ID: 33091668
[TBL] [Abstract][Full Text] [Related]
19. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
20. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]